Stacey Johnson
Stacey Johnson is the editor of Signals and a contributor. For 25 years, Stacey has been providing strategic communications counsel to government, corporate, technology and health organizations. She began her career at the CTV Television Network and then moved to Hill & Knowlton Canada where she advised clients in a variety of industries and sectors. Stacey is the Vice President, Communications and Marketing for CCRM, a leader in developing and commercializing regenerative medicine-based technologies and cell and gene therapies. She has a Master's degree in Public Relations. You can follow her on Twitter @msstaceyerin.
Posts by: Stacey
I’ve been thinking about unapproved stem cell treatments a lot recently. First, I read this article that hailed the arrival of stem cell treatments in a small community in western Canada. There were many statements in the article that concerned me, but I only addressed a few major ones in my letter to the editor. […]
You’re back! Whether you stumbled onto this post or you sought it out following my introductory blog about Knowledge Translation (KT), I’m just glad you’re here. Now that you understand what KT is (hint: click on the link above if you need a definition) and why it’s essential that academics share their findings in a […]
I’m delighted that, despite the title, you’ve decided to read this post! For some academics, knowledge translation is not the most exciting aspect of their job, but it is a requirement that must be fulfilled as part of their funding obligations. No offense to those who are professionals in the field and embrace the importance […]
Understanding cell therapy regulation is an essential component of the bench to bedside pipeline. Without approval from a country’s regulator (Health Canada, FDA, EMA, PMDA, etc.), a product cannot be sold to consumers and the millions invested in research and development, manufacturing and clinical trials is media down the drain. Cell therapies present a range […]
It has been said that the pen is mightier than the sword. Where, then, does the gun factor in? I was amazed, last year, when I learned of the “biopen,” a medical device that draws stem cells to repair damaged or worn cartilage and then the cartilage heals itself with its own cells. From what […]
Right Turn: Clinical trials – one solution to unapproved stem cell treatments
I’ve been thinking about unapproved stem cell treatments a lot recently. First, I read this article that hailed the arrival of stem cell treatments in a small community in western Canada. There were many statements in the article that concerned me, but I only addressed a few major ones in my letter to the editor. […]